Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer

Although the immunotherapy combination regimen has shown good data and safety during the perioperative period of gastric cancer, more clinical studies are still needed to explore the treatment regimens, the number of treatment cycles, the screening of beneficiary populations, and the safety assessment of different drug combinations of immunotherapy combination therapy as adjuvant treatment after gastric cancer surgery.